Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis
NCT ID: NCT01438437
Last Updated: 2012-07-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
54 participants
INTERVENTIONAL
2001-03-31
2015-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Sample size Taking RFA as a standard procedure with an estimated success rate of 95%, a sample size of minimum 27 for each arm is required to detect an equivalence difference of 10%, assuming that PAI has a success rate of 85%. This sample size is expected to provide a power of 80%.
Randomization
* Stratified randomization of Child A and B will be done.
* Randomization into A (Acetic acid) and B (Radiofrequency ablation) will be done.
Diagnostic criteria
* Cirrhosis of liver- Diagnosis will be founded on the basis of clinical, biochemical, imaging and endoscopy findings.
Hepatocellular carcinoma- when any one of the following is present
1. Two imaging modalities (dual phase CT (DPCT)/ contrast enhanced Magnetic Resonance Imaging (MRI)) showing arterialization of the hepatic mass
2. AFP more than 400ng/ml along with arterialisation on one imaging modality (DPCT/ contrast enhanced MRI)
3. Fine needle aspiration cytology (FNAC)
Definitions
1. Local recurrence : When the Triple phase CT shows-
* An area of nodular enhancement that abuts or surrounds the ablation defect or protrudes into the low attenuating necrotic tissue (may sometimes be seen only on arterial phase of CT)
* Recurrent soft tissue causing distortion of the otherwise smooth interphase with the adjoining liver parenchyma.
2. Fresh lesion- When a new lesion is seen in the liver at a site other than the primary site of the treated lesion with normal liver parenchyma intervening in between will be considered as a fresh lesion.
3. Residual disease or incomplete ablation When the follow up Triple phase CT shows-
* Residual nodular enhancement that abuts or surrounds the low attenuating ablation defect or protrudes into the low attenuating necrotic tissue (may sometimes be seen only on arterial phase of CT)
* Residual soft tissue causing distortion of the otherwise smooth interphase with the adjoining liver parenchyma.
* Concenteric hyperemia around the low attenuating defect showing area of focal nodularity or asymmetric thickness.
4. End point of ablation When the Triple phase CT shows-
* A homogenous, well defined, uniformly low attenuating defect larger than the pretreatment size.
* No residual soft tissue seen within or at the periphery of the low attenuating defect
* Concentric hyperemia around the low attenuating defect of uniform thickness with no focal nodularity.
Follow up
1. Clinical follow up
* All patients would be followed up in the Liver clinic monthly unless their clinical condition warrants earlier follow up
* Liver function tests/ complete blood count would also be done at each visit and Alfafetoprotein (AFP) every six months
* Patient tolerance, child's status would be estimated.
2. Imaging follow up
* At one month, a dual phase CT would be done to ascertain the local response to therapy and the need to repeat the procedure. After achieving the end point after ablation (PAI and RFA, the DPCT would be done at 3 and 6 monthly intervals.
Duration of follow up - Since more than 80% recurrence occurs in 2 years therefore the duration of follow up would be 2 years after ablation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Percutaneous acetic acid
PAI
Under local anaesthesia, taking proper aseptic precautions, 40% acetic acid (total dose not exceeding 3 times the diameter of the mass, (not more than 2ml in one sitting), will be injected into the mass through the percutaneous route
Radiofrequency ablation
RFA
Under aseptic conditions and local anesthesia, the needle electrode would be introduced percutaneously into the tumor under ultrasound guidance.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PAI
Under local anaesthesia, taking proper aseptic precautions, 40% acetic acid (total dose not exceeding 3 times the diameter of the mass, (not more than 2ml in one sitting), will be injected into the mass through the percutaneous route
RFA
Under aseptic conditions and local anesthesia, the needle electrode would be introduced percutaneously into the tumor under ultrasound guidance.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Number of liver masses not more than 5 and the size of each \<5cm in diameter.
* No extrahepatic disease.
* Absence of malignant portal vein thrombosis.
* Platelet count more than 70,000/mm3
* Prothrombin time more than 50%.
* Written consent of patient.
Exclusion Criteria
* Liver mass \>5cm in diameter.
* Number of liver masses more than 3
* Peripherally located masses with no hepatic parenchyma around
* Liver mass not discernable on ultrasound.
* Extra hepatic disease like RP adenopathy, distant metastasis.
* Coagulation disorders.
* Unwilling patient
12 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
All India Institute of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Subrat Kumar Acharya
Proffessor and Head
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AIIMS
New Delhi, National Capital Territory of Delhi, India
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Subrat K Acharya, DM
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
23-16/11/2001
Identifier Type: -
Identifier Source: org_study_id